GSK plc (GSK) is a Biotechnology: Pharmaceutical Preparations company listed on NYSE. In the last 30 days Quantisnow tracked 25 wire items for GSK, including 16 SEC filings, 7 press releases and news items and 2 analyst ratings. The most recent was published Nov 6, 2026.
GSK rankings
Financial highlights
Full financials- Revenue, FY2025
- £32.67B
- Revenue growth
- +4.1%
- Net income, FY2025
- £5.72B
- Net margin
- 17.5%
- Free cash flow, FY2025
- £6.39B
- Cash
- £3.40B
For fiscal 2025 (ended Dec 31, 2025), from SEC filings. Not investment advice.
News · 26 weeks117+83%
2026-05-102026-11-01
Mix5390d
- SEC Filings38(72%)
- Other10(19%)
- Analyst4(8%)
- Offering1(2%)
Latest news
25 items- SECSEC Form 6-K filed by GSK plc6-K - GSK plc (0001131399) (Filer)
- SECSEC Form 13F-HR filed by GSK plc13F-HR - GSK plc (0001131399) (Filer)
- FDAFDA Approval for BENLYSTA issued to GLAXOSMITHKLINE LLCSubmission status for GLAXOSMITHKLINE LLC's drug BENLYSTA (SUPPL-38) with active ingredient BELIMUMAB has changed to 'Approval' on 10/30/2026. Application Category: BLA, Application Number: 761043, Application Classification:
- PRAlamar Biosciences Partners with GSK on Large-Scale Proteomic Study to Advance Precision MedicineFREMONT, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (NASDAQ:ALMR), a leader in precision proteomics dedicated to enabling the earliest detection of disease, today announced a strategic scientific collaboration with GSK plc (LSE/NYSE:GSK) that will use Alamar’s NULISA™ platform in a large-scale study examining how circulating protein signatures relate to disease progression, biological subtypes and treatment response across respiratory, liver, kidney, neurological and autoimmune conditions. The collaboration intends to generate deep proteomic insights to advance precision prevention, treatment and earlier disease detection in real-world health care settings. Many d
- SECSEC Form 6-K filed by GSK plc6-K - GSK plc (0001131399) (Filer)
- PRAlfasigma Announces New Linerixibat Data Across PBC and Liver Disease to be Presented at AASLD’s The Liver Meeting 2026MORRISTOWN, N.J., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Alfasigma, a global pharmaceutical company, today announced that five presentations on linerixibat in primary biliary cholangitis (PBC), including one oral presentation and four posters, will be presented by GSK plc (LSE/NYSE:GSK) at American Association for the Study of Liver Diseases (AASLD) The Liver Meeting 2026, November 5–9 in Denver. The presentations will highlight new analyses on clinically meaningful improvement in cholestatic pruritus, unmet needs and treatment gaps in PBC, and the effects of linerixibat on biomarkers, metabolic profiles and fat-soluble vitamin absorption. "Cholestatic pruritus remains a major clinical burden
- ANALYSTGSK plc downgraded by Jefferies with a new price targetJefferies downgraded GSK plc from Buy to Hold and set a new price target of $55.90
- SECSEC Form 6-K filed by GSK plc6-K - GSK plc (0001131399) (Filer)
- SECSEC Form 6-K filed by GSK plc6-K - GSK plc (0001131399) (Filer)
- SECSEC Form 6-K filed by GSK plc6-K - GSK plc (0001131399) (Filer)
- SECSEC Form 6-K filed by GSK plc6-K - GSK plc (0001131399) (Filer)
- SECSEC Form 6-K filed by GSK plc6-K - GSK plc (0001131399) (Filer)
- SECSEC Form 6-K filed by GSK plc6-K - GSK plc (0001131399) (Filer)
- PRHibsago (bepirovirsen) Approved in the US for the Treatment of Chronic Hepatitis B (CHB)Approval based on phase III data showing unprecedented functional cure rates compared to standard of care Six-month treatment with option of self-administration after first dose CHB affects approximately 1.7 million people in the US1 GSK plc (LSE/NYSE:GSK) today announced that the US Food and Drug Administration (FDA) has approved Hibsago (bepirovirsen) for the treatment of chronic hepatitis B (CHB) virus infection in combination with nucleos(t)ide analogue reverse transcriptase inhibitor (NrtI) therapy in adult patients without cirrhosis, receiving NrtI therapy for at least 6 months, who have suppressed HBV deoxyribonucleic acid (DNA), and with hepatitis B virus (HBV) surface ant
- PRJemperli (dostarlimab-gxly) approved in US as first and only immunotherapy for adults with MSI-H/dMMR locally advanced rectal cancerApproval based on AZUR-1 data showing clinically significant proportion of participants with no detectable signs of cancer one year or more after treatment No disease recurrences reported among responders after median follow up of more than two years Jemperli monotherapy could help eligible patients avoid chemotherapy, radiation and surgery GSK plc (LSE/NYSE:GSK) today announced the US Food and Drug Administration (FDA) has approved Jemperli (dostarlimab-gxly) as the first and only immunotherapy for adults with stage II and III microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) locally advanced rectal cancer under the accelerated approval pathway. Current s
- SECSEC Form 6-K filed by GSK plc6-K - GSK plc (0001131399) (Filer)
- SECSEC Form 6-K filed by GSK plc6-K - GSK plc (0001131399) (Filer)
- SECSEC Form 6-K filed by GSK plc6-K - GSK plc (0001131399) (Filer)
- SECSEC Form 6-K filed by GSK plc6-K - GSK plc (0001131399) (Filer)
- SECSEC Form S-8 filed by GSK plcS-8 - GSK plc (0001131399) (Filer)
- SECSEC Form 6-K filed by GSK plc6-K - GSK plc (0001131399) (Filer)
- SECSEC Form 6-K filed by GSK plc6-K - GSK plc (0001131399) (Filer)
- ANALYSTWolfe Research initiated coverage on GSK plc with a new price targetWolfe Research initiated coverage of GSK plc with a rating of Outperform and set a new price target of $70.00
- SECSEC Form 6-K filed by GSK plc6-K - GSK plc (0001131399) (Filer)
- PRViola Davis partners with GSK to educate adults 50 and older about their shingles riskFor the first time, Viola Davis shares her experience with shinglesViola encourages adults 50 years and older to prioritize their health and have candid conversations about increased risks that come with agingThe partnership is part of GSK's new national "Shingles, actually" disease education campaignPHILADELPHIA, Oct. 8, 2026 /PRNewswire/ -- GSK plc (LSE/NYSE:GSK) today announced a partnership with award-winning actress, producer and philanthropist Viola Davis to launch "Shingles, actually", a new educational campaign designed to spark conversations about the realities of aging, including the risk of shingles for adults 50 years and older. As part of the "Shingles, actually" campaign, Viola
GSK FAQ
11 questionsWhat does GSK plc do?
GlaxoSmithKline plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system...What is the latest news on GSK?
In the last 30 days Quantisnow tracked 25 wire items for GSK: 16 SEC filings, 7 press releases and news items and 2 analyst ratings. The most recent was published on November 6, 2026.What is GSK revenue?
GSK plc (GSK) reported £32.67B of revenue for fiscal 2025 (ended Dec 31, 2025). That is up 4.1% from the year before.Is GSK profitable?
Yes. GSK plc earned £5.72B in net income for fiscal 2025 (ended Dec 31, 2025), a net margin of 17.5%.How much cash and debt does GSK have?
GSK plc reported £3.40B in cash and cash equivalents and £14.71B of debt on its most recent balance sheet in SEC filings.Where does GSK stock trade?
GSK plc (GSK) is listed on NYSE.What sector and industry is GSK in?
GSK plc operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did GSK plc go public?
GSK plc (GSK) completed its IPO in 2022.What are analysts saying about GSK?
Across the last 8 analyst actions on GSK plc, there were 2 upgrades and 2 downgrades. The most recent action was from Jefferies: Hold with a $55.90 price target on 2026-10-29. Recent price targets range from $55.90 to $70.00.What companies are similar to GSK?
Notable peers in the same industry include JNJ (Johnson & Johnson), NVS (Novartis AG), AZN (AstraZeneca PLC), SNY (Sanofi). Compare GSK side-by-side with any of them on Quantisnow.How can I track GSK on Quantisnow?
Quantisnow aggregates GSK plc's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow GSK to receive live email and push alerts on every new disclosure.